Health Canada has granted marketing authorization for Spevigo to treat adult patients with flares for generalized pustular psoriasis
The approval was based on the 12wk. P-II trial (EFFISAYIL-1) evaluating spesolimab (900mg, IV) vs PBO in a ratio (2:1) in 53 patients which showed that 54% vs 6% of patients showed no visible pustules after 1wk. while 84.4% had no visible pustules and 81.3% with clear/almost clear skin after 12wk., inf. was reported in 17% vs 6% at 1wk.
Spesolimab is a novel, humanized, selective Ab that blocks the activation of IL-36R. Spesolimab is also being studied for the treatment of other neutrophilic skin conditions as well as for the prevention of GPP flares
Ref: Newswire | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim’s Spevigo (spesolimab) Receives EC’s Conditional Marketing Authorization for Generalized Pustular Psoriasis Flares
